{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T10:42:52Z","timestamp":1774608172389,"version":"3.50.1"},"reference-count":30,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2015,6,5]],"date-time":"2015-06-05T00:00:00Z","timestamp":1433462400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2015,11]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>We previously reported a 28\u2010day treatment protocol for children with endemic Burkitt lymphoma (BL) which included four doses of cyclophosphamide (CPM), intrathecal methotrexate and hydrocortisone (IT MTX\/HC) at Queen Elizabeth Central Hospital (QECH) in Malawi which resulted in an Event\u2010Free Survival (EFS) of 50% at 1 year.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In an attempt to improve survival whilst maintaining acceptable toxicity, brevity, low\u2010cost and a standard treatment for all patients, four doses of vincristine (VCR) at 1.5\u2009mg\/m<jats:sup>2<\/jats:sup> were added to the backbone of CPM 40\u2009mg\/kg on day 1 and 60\u2009mg\/kg on days 8,18 and 28 and IT MTX \/HC 12.5\u2009mg on days 1,8,18 and 28.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Seventy cytology confirmed cases of BL, 42 males and 28 females with a median age of 80\u2009years, were treated with this protocol between January 2010 and April 2012. Four percent had St Jude Stage I disease; 29% Stage II; 30% Stage III and 37% Stage IV. Disease site in order of frequency was face (64%); abdomen (47%); CSF (26%) and paraspinal (17%). There were two on\u2010treatment deaths. Sixty\u2010three percent required antibiotics and 19% required blood transfusion. Eighty\u2010one percent of patients achieved complete clinical remission at day 28. Overall predicted EFS at 1\u2009year was 48%; 100% in Stage I, 83% in Stage II, 24% in Stage III and 32% in Stage IV disease. EFS was significantly worse in patients with Stage III\/IV disease (<jats:italic>P\u2009<\/jats:italic>=\u20090.002) and paraplegia (<jats:italic>P\u2009<\/jats:italic>=\u20090.002).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The addition of vincristine to the Malawi 28 day BL treatment protocol did not improve survival. Pediatr Blood Cancer \u00a9 2015 Wiley Periodicals, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pbc.25612","type":"journal-article","created":{"date-parts":[[2015,6,5]],"date-time":"2015-06-05T15:25:26Z","timestamp":1433517926000},"page":"1929-1934","source":"Crossref","is-referenced-by-count":17,"title":["Outcome is unchanged by adding vincristine upfront to the Malawi 28\u2010day protocol for endemic Burkitt lymphoma"],"prefix":"10.1002","volume":"62","author":[{"given":"Sarita","family":"Depani","sequence":"first","affiliation":[{"name":"Department of Paediatric Queen Elizabeth Central Hospital Blantyre Malawi"},{"name":"Children and Young People's Cancer Service University College Hospital London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kondwani","family":"Banda","sequence":"additional","affiliation":[{"name":"Department of Paediatric Queen Elizabeth Central Hospital Blantyre Malawi"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Bailey","sequence":"additional","affiliation":[{"name":"Department of Paediatric Oncology Great North Childrens Hospital Newcastle UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trijn","family":"Israels","sequence":"additional","affiliation":[{"name":"Department of Paediatric Oncology Outreach Programme VU University Medical Centre Amsterdam the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Chagaluka","sequence":"additional","affiliation":[{"name":"Department of Paediatric Queen Elizabeth Central Hospital Blantyre Malawi"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Molyneux","sequence":"additional","affiliation":[{"name":"Department of Paediatric Queen Elizabeth Central Hospital Blantyre Malawi"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,6,5]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20917"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61177-X"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910260302"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197602)37:2<671::AID-CNCR2820370210>3.0.CO;2-D"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(79)92627-8"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19850715)56:2<239::AID-CNCR2820560205>3.0.CO;2-F"},{"key":"e_1_2_8_8_1","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1182\/blood-2006-07-036673","article-title":"Fab Lmb International Study Committee. Results of the randomized international FAB\/LMB96 trial for intermediate risk B\u2010cell non\u2010Hodgkin lymphoma in children and adolescents: It is possible to reduce treatment for the early responding patients","volume":"109","author":"Patte C","year":"2007","journal-title":"Blood"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07144.x"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22032"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11833"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.03.027"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.10322"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20254"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22746"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.3109\/08880018.2011.644881"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1179\/146532809X402006"},{"key":"e_1_2_8_18_1","first-page":"412","article-title":"High frequency cyclophosphamide and plus intrathecal methotrexate in endemic Burkitt lymphoma. Analysis of of multicentre trial in Malawi, Cameroon and Ghana","volume":"44","author":"Hesseling PBME","year":"2005","journal-title":"Pediatr Blood Cancer"},{"key":"e_1_2_8_19_1","first-page":"381","article-title":"Oral cyclophosphamide and intrathecal methotrexate in 140 children with Burkitt lymphoma","volume":"47","author":"Hesseling PBME","year":"2006","journal-title":"Pediatr Blood Cancer"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24407"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trstmh.2008.02.009"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(196608)19:8<1131::AID-CNCR2820190813>3.0.CO;2-I"},{"key":"e_1_2_8_23_1","first-page":"332","article-title":"Classification, staging and end results of treatment of childhood non\u2010Hodgkin's lymphomas: Dissimilarities from lymphomas in adults","volume":"7","author":"Murphy SB","year":"1980","journal-title":"Semin Oncol"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24501"},{"key":"e_1_2_8_25_1","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 DCTD NCI NIH DHHS May 28 2009. Available from:http:\/\/evs.nci.nih.gov"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09236.x"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/130680"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19800315)45:6<1507::AID-CNCR2820450634>3.0.CO;2-D"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trstmh.2011.08.008"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70128-0"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21127"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.25612","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.25612","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.25612","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T02:07:46Z","timestamp":1696471666000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.25612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,5]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["10.1002\/pbc.25612"],"URL":"https:\/\/doi.org\/10.1002\/pbc.25612","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,5]]}}}